Polkey et al. observed that bimagrumab, a blocker of the activin type II receptor (a membrane receptor for myostatin), significantly increased the volume of thigh muscles in patients with COPD [77]. The gene discussed is MSTN; the disease is chronic obstructive pulmonary disease.